基本信息
views: 1
Career Trajectory
Bio
I have been involved in the field of advanced heart failure for over 35 years, including over 90 clinical trials focusing on all forms of oral and intravenous pharmacologic therapy, including all types of immunosuppression for organ transplantation, and use of mechanical assist devices. My career has evolved over the past 10 years to focus almost entirely on the field of regenerative medicine for organ and tissue regeneration.
I have had a leadership role in this field beginning with being the founder of the Working Group of Transplant Cardiologists that helped evolve the field into a cardiology-based discipline from purely surgical, and grew to becoming the Program Chair for the International Heart Transplant Society meeting, and eventually the President of this organization. I also took a leadership role in entire the field of transplantation, and became the first non-nephrologist to hold the office of President of the American Society of Transplant Physicians.
I have also had leadership positions throughout my career including being the Chief of Cardiology for a total of over 15 years at the Universities of Minnesota, Georgetown, and University of South Florida. I have been the Director of Heart Failure, Transplant, and Mechanical Support from my first job at St Louis University, and each of the subsequent programs at which I was Chief of Cardiology. While at the University of MN I created the Lillehei Heart Institute which became the focus of all cardiovascular basic and clinical research there. I have also served as the Director of Fellowship training for over 20 years and mentored over 750 cardiology trainees in my career.
My academic accomplishments include publication of over 250 manuscripts, 12 book chapters, and lead editor for two major textbooks in the field; Mechanical Circulatory Support and Stem Cell and Gene Therapy for Cardiovascular Disease. I have been involved in clinical and basic research throughout my career, including being the Principle Investigator in 94 clinical trials, including trials funded by the NIH, AHA, as well as industry, as well as on the Steering Committee for over 20 trials and National PI for 4 sstudies. I have been a manuscript reviewer for most major journals in the field of cardiology, and on the editorial board for 3 journals. I have been an abstract reviewer for over 15 years for most major meetings in the field of heart failure and cardiology. I have presented at nearly every meeting of the major society in the field including AHA, ACC, ISHLT, HFSA for the past 20 years, and lectured at most of the major universities in the US and Europe on topics ranging from heart failure to regenerative medicine.
My basic research began during a 14 month sabbatical with Dr Phillip Halloran in Alberta, Canada studying molecular mechanisms of immunosuppressive drugs, and Dr Alexandra Lucas on vascular biology and the role of a class of peptides known as Serpins in the pathogenesis of cardiac transplant related allograft arteriopathy. I was recruited to be Chief of Cardiology at the U of MN and hired and worked closely with Dr Jennifer Hall on NIH funded research examining the molecular basis of remodeling of patients with end stage heart failure who had an LVAD placed, using microarray analysis of pre and post implant tissue specimens to identify gene expression patterns associated with recovery. We identified the stem cell homing gene, Stromal Derived Factor(SDF-1) as the gene most upregulated in responders vs down regulated in non-responders. I also worked with Dr Jay Zhong on early investigation on the use of scaffolds of matrix imbedded with stem cells, as a superior alternative to intramuscular injection, and retrograde delivery versus intracoronary to develop a cheaper and easier method of delivery of cells or genes. I have collaborated with Dr Doris Taylor on her work on use of stem cells for cardiac regeneration, which spawned my evolution to regenerative medicine becoming the focus of my career and research interests. I became the site PI for the NHLBI SCOR grant on the first use of allogeneic mesenchymal stem cells in patients with heart failure at the time of implant of a ventricular assist device in 2008. Since that time I have been involved as the site or national PI for 12 trials of stem cell of gene therapy for cardiovascular disease, including not only heart failure but also acute MI, Peripheral Arterial Disease in addition to heart failure, using adipose derived and bone marrow cells, as well as currently the allogeneic MSCs in the DREAM trial, but also five different genes including SERCA-2A, Neuregulin, SDF-1, as well as a combination of S100A, SDF, and VEGF.
My intense interest in regenerative medicine led to me creating the outline for a textbook on this topic and became the lead editor for what is currently one of the leading textbooks in the field entitled, Stem Cells and Gene Therapy for Cardiovascular Disease. This led to extensive research on all areas of this field including tissue engineering, and a detailed grasp of nearly all the current and future strategies to enhance cell retention and harness native organ and tissue regeneration.
During the research for this book I became aware of the unique approach of using bioelectric stimulation to stimulate the upregulation in the local tissue of a variety of very pro-regenerative proteins, including SDF to enhance homing of stem cells to the target area, but also the unique signaling to enhance differentiation and proliferation of these stem cells. This interest led to collaboration with Howard Leonhardt, who is a pioneer in this concept and becoming the PI on a grant funded at the University of Utah to study cardiac regeneration with the use of Biolecrtric Stimulation(BES). We first examined iPSC-derived cardiomyocytes to prove the efficacy of the stimulation in upregulation of a set of 15 target protein expression by QPCR analysis, and will use his very novel approach to use deliver BES plus stem cells and a combination of most individual agents shown to play a role in stem cell function and organ regeneration including exosomes, mRNA, matrix, as well as amniotic fluid. I have become the Chief Medical Officer for Leonhardt Ventures and in this role I am involved in all of the research with the use of the combinatorial approach to organ and tissue regeneration across nearly all organs and diseases, including collaboration and grant applications with many universities and research labs. We have worked to identify genes that are uniquely important in specific conditions, such as IGF for brain injury and recovery, as well as liver regeneration. We are focusing on GDF-10,11 as potentially important in aging and regeneration in most organs.
I have had a leadership role in this field beginning with being the founder of the Working Group of Transplant Cardiologists that helped evolve the field into a cardiology-based discipline from purely surgical, and grew to becoming the Program Chair for the International Heart Transplant Society meeting, and eventually the President of this organization. I also took a leadership role in entire the field of transplantation, and became the first non-nephrologist to hold the office of President of the American Society of Transplant Physicians.
I have also had leadership positions throughout my career including being the Chief of Cardiology for a total of over 15 years at the Universities of Minnesota, Georgetown, and University of South Florida. I have been the Director of Heart Failure, Transplant, and Mechanical Support from my first job at St Louis University, and each of the subsequent programs at which I was Chief of Cardiology. While at the University of MN I created the Lillehei Heart Institute which became the focus of all cardiovascular basic and clinical research there. I have also served as the Director of Fellowship training for over 20 years and mentored over 750 cardiology trainees in my career.
My academic accomplishments include publication of over 250 manuscripts, 12 book chapters, and lead editor for two major textbooks in the field; Mechanical Circulatory Support and Stem Cell and Gene Therapy for Cardiovascular Disease. I have been involved in clinical and basic research throughout my career, including being the Principle Investigator in 94 clinical trials, including trials funded by the NIH, AHA, as well as industry, as well as on the Steering Committee for over 20 trials and National PI for 4 sstudies. I have been a manuscript reviewer for most major journals in the field of cardiology, and on the editorial board for 3 journals. I have been an abstract reviewer for over 15 years for most major meetings in the field of heart failure and cardiology. I have presented at nearly every meeting of the major society in the field including AHA, ACC, ISHLT, HFSA for the past 20 years, and lectured at most of the major universities in the US and Europe on topics ranging from heart failure to regenerative medicine.
My basic research began during a 14 month sabbatical with Dr Phillip Halloran in Alberta, Canada studying molecular mechanisms of immunosuppressive drugs, and Dr Alexandra Lucas on vascular biology and the role of a class of peptides known as Serpins in the pathogenesis of cardiac transplant related allograft arteriopathy. I was recruited to be Chief of Cardiology at the U of MN and hired and worked closely with Dr Jennifer Hall on NIH funded research examining the molecular basis of remodeling of patients with end stage heart failure who had an LVAD placed, using microarray analysis of pre and post implant tissue specimens to identify gene expression patterns associated with recovery. We identified the stem cell homing gene, Stromal Derived Factor(SDF-1) as the gene most upregulated in responders vs down regulated in non-responders. I also worked with Dr Jay Zhong on early investigation on the use of scaffolds of matrix imbedded with stem cells, as a superior alternative to intramuscular injection, and retrograde delivery versus intracoronary to develop a cheaper and easier method of delivery of cells or genes. I have collaborated with Dr Doris Taylor on her work on use of stem cells for cardiac regeneration, which spawned my evolution to regenerative medicine becoming the focus of my career and research interests. I became the site PI for the NHLBI SCOR grant on the first use of allogeneic mesenchymal stem cells in patients with heart failure at the time of implant of a ventricular assist device in 2008. Since that time I have been involved as the site or national PI for 12 trials of stem cell of gene therapy for cardiovascular disease, including not only heart failure but also acute MI, Peripheral Arterial Disease in addition to heart failure, using adipose derived and bone marrow cells, as well as currently the allogeneic MSCs in the DREAM trial, but also five different genes including SERCA-2A, Neuregulin, SDF-1, as well as a combination of S100A, SDF, and VEGF.
My intense interest in regenerative medicine led to me creating the outline for a textbook on this topic and became the lead editor for what is currently one of the leading textbooks in the field entitled, Stem Cells and Gene Therapy for Cardiovascular Disease. This led to extensive research on all areas of this field including tissue engineering, and a detailed grasp of nearly all the current and future strategies to enhance cell retention and harness native organ and tissue regeneration.
During the research for this book I became aware of the unique approach of using bioelectric stimulation to stimulate the upregulation in the local tissue of a variety of very pro-regenerative proteins, including SDF to enhance homing of stem cells to the target area, but also the unique signaling to enhance differentiation and proliferation of these stem cells. This interest led to collaboration with Howard Leonhardt, who is a pioneer in this concept and becoming the PI on a grant funded at the University of Utah to study cardiac regeneration with the use of Biolecrtric Stimulation(BES). We first examined iPSC-derived cardiomyocytes to prove the efficacy of the stimulation in upregulation of a set of 15 target protein expression by QPCR analysis, and will use his very novel approach to use deliver BES plus stem cells and a combination of most individual agents shown to play a role in stem cell function and organ regeneration including exosomes, mRNA, matrix, as well as amniotic fluid. I have become the Chief Medical Officer for Leonhardt Ventures and in this role I am involved in all of the research with the use of the combinatorial approach to organ and tissue regeneration across nearly all organs and diseases, including collaboration and grant applications with many universities and research labs. We have worked to identify genes that are uniquely important in specific conditions, such as IGF for brain injury and recovery, as well as liver regeneration. We are focusing on GDF-10,11 as potentially important in aging and regeneration in most organs.
Research Interests
Papers共 206 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cardiovascular Revascularization Medicine (2021): S25
JAMA Cardiologyno. 7 (2018)
Circulation researchno. 4 (2018): 495-505
Load More
Author Statistics
#Papers: 187
#Citation: 23240
H-Index: 62
G-Index: 152
Sociability: 7
Diversity: 1
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn